Patents Represented by Attorney Elie Gendloff, Esq.
  • Patent number: 8343922
    Abstract: Compositions and methods for the treatment of bone diseases, bone fractures, bone injuries and other bone abnormalities involving the use of Dkk protein, a Wnt antagonist, a Wnt inhibitor, or any other related protein for the stimulation or enhancement of mineralization and for stimulating the renewal of cells. One Dkk protein, Dickkopf-2 (Dkk-2), acts to stimulate bone formation independently of Wnt proteins which may be inhibited and/or antagonized by Dkk-2. Dkk-2 displayed enhanced specific targeting ability and enhanced biological activity in stimulating or enhancing mineralization. Dkk-2 also played a role in the differentiation and self-renewal of hematopoietic stem cells and mesenchymal stem cells, particularly in osteoblastogenesis and osteoclastogenesis.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: January 1, 2013
    Assignee: Enzo Biochem, Inc.
    Inventors: Dianqing Wu, Xiaofeng Li, Peng Liu, Wenzhong Liu, Dean Engelhardt
  • Patent number: 8314151
    Abstract: Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM).
    Type: Grant
    Filed: August 31, 2009
    Date of Patent: November 20, 2012
    Assignee: Enzo Therapeutics, Inc.
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • Patent number: 8288092
    Abstract: The invention is directed to nucleic acid sequences having decreased thermodynamic stability to complementary sequence as well as a method for producing these sequences.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: October 16, 2012
    Assignee: Enzo Life Sciences, Inc.
    Inventors: Elazar Rabbani, Jannis G. Stavrianopoulos, James J. Donegan, Jack Coleman, Marleen Walner